NMRA Stock Summary and Trading Ideas (Neumora Therapeutics | NASDAQ:NMRA)

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Neumora Therapeutics trades on the NASDAQ stock market under the symbol NMRA.

As of January 29, 2026, NMRA stock price climbed to $2.05 with 590,221 million shares trading.

NMRA has a beta of 3.00, meaning it tends to be more sensitive to market movements. NMRA has a correlation of 0.18 to the broad based SPY ETF.

NMRA has a market cap of $348.37 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that NMRA belongs to (by Net Assets): VTI, VXF, SCHA, IBB, PRFZ.

NMRA has underperformed the market in the last year with a price return of +6.2% while the SPY ETF gained +16.5%. NMRA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -18.0% and -3.8%, respectively, while the SPY returned +1.3% and +0.3%, respectively.

NMRA support price is $1.89 and resistance is $2.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NMRA shares will trade within this expected range on the day.